Research & Regulatory News

The EMA Opinion on Oral Semaglutide for Weight Management

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

On 21 May 2026 the CHMP adopted a positive opinion recommending an extension to Wegovy's marketing authorisation, adding tablets for oral use in four strengths, 1.5 mg, 4 mg, 9 mg and 25 mg. It would be the first GLP-1 receptor agonist for weight management developed for oral use.

Key facts

Opinion adopted
21 May 2026
Meeting
CHMP, 18-21 May 2026
Type
Variation (new pharmaceutical form and route)
Strengths
1.5 mg, 4 mg, 9 mg, 25 mg
Existing form
Weekly subcutaneous injection
Status
Opinion, not yet a decision

What a CHMP positive opinion is

A recommendation from the EMA's scientific committee, not the authorisation itself. The European Commission takes the legal decision afterwards, and it follows the opinion in the great majority of cases. Reporting a positive opinion as an approval is a common and slightly premature conflation.

A variation adding a new pharmaceutical form with a new route of administration. Tablets for oral use, in four strengths: 1.5 mg, 4 mg, 9 mg and 25 mg. This extends an existing authorisation rather than creating a new one, since Wegovy is already authorised as a weekly subcutaneous injection.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

A distinction worth getting right

Secondary coverage has described this opinion as covering oral Wegovy and a 7.2 mg pen together. It does not. The recommendation concerns oral tablets in the four strengths listed. The 7.2 mg figure belongs to STEP UP, a separate phase 3b trial of a higher-dose once-weekly injectable, a different formulation, a different route and a different regulatory question.

Why an oral peptide is difficult

Peptides are digested. Oral semaglutide addresses this with the absorption enhancer SNAC and strict administration conditions, and even then absorption is a small and variable fraction of the dose. That is why the tablet strengths are so much larger than the injectable dose. The numbers are not comparable across routes.

How this sits against the small molecules

Orforglipron and aleniglipron avoid the problem by not being peptides at all, so they need no absorption enhancer and no administration conditions. Oral semaglutide keeps peptide pharmacology and solves delivery by formulation. Both routes to an oral GLP-1 are now real, and they involve entirely different trade-offs.

What this does not concern

Research material. This is a regulatory step for a licensed medicine assessed by the EMA. Nothing supplied here is semaglutide in any form, and no research compound is an alternative to a prescribed weight-management medicine.

Frequently asked questions

Does the opinion include a 7.2 mg pen?

No. That figure belongs to STEP UP, a separate trial of a higher-dose once-weekly injectable, a different route and a different regulatory question.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Research & Regulatory News articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.